GlassScriptPhysician profile
Charles Yun
NPI 1710121330
$594.92
in general payments reported to CMS, 2019-2025
20 companies · $99.34 in 2025
The $99.34 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.16 · 2020: $144 · 2021: $134 · 2022: $57.06 · 2023: $40.07 · 2024: $40.27 · 2025: $99.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138 · Education: $42.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.66 |
| Education | $42.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $138.27 | 2020-2024 | Tecvayli, Talvey, Imbruvica |
| Pfizer INC. | $98.85 | 2020-2025 | |
| Seagen INC. | $34.55 | 2021-2022 | |
| Exelixis INC. | $29.88 | 2021-2025 | Cabometyx |
| Tersera Therapeutics LLC | $25.45 | 2022 | |
| Eisai INC. | $24.85 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $22.28 | 2025 | Onivyde |
| Epizyme, INC. | $21.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.54 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $17.46 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Amgen INC. | $16.85 | 2021 | |
| Abbvie INC. | $16.22 | 2025 | |
| Genzyme Corporation | $16.18 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $16.02 | 2021 | |
| Astellas Pharma US INC | $15.93 | 2021 | |
| Beigene USA, INC. | $15.45 | 2020 | |
| Dova Pharmaceuticals | $14.75 | 2020 | |
| Clovis Oncology, INC. | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Yun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.